Jun 16, 2020
Intermolecular Announces Breakthrough Four-Element ALD Chalcogenide-based OTS for 3D Memory Arrays
May 28, 2020
Merck KGaA, Darmstadt, Germany, and Twitch Join Forces on World Multiple Sclerosis Day to Connect People Living with MS
May 27, 2020
Rebif® U.S. Label Now Includes Pregnancy Outcomes and Lactation Information to Help Inform Treatment Decisions for Women with MS
May 23, 2020
New Late-Breaking Data at EAN Indicate Evobrutinib is the First BTK Inhibitor to Report Efficacy and Safety in MS Over 108 Weeks
May 13, 2020
Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to Be Presented at ASCO 2020
Apr 30, 2020
Data From EMD Serono at ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care
Apr 09, 2020
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO® for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Mar 25, 2020
TEPMETKO® (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations
Mar 13, 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Feb 06, 2020
EMD Serono Receives Positive Recommendation for MAVENCLAD® (cladribine tablets) for the treatment of Relapsing-Remitting Multiple Sclerosis from the Institut national d'excellence en santé et en services sociaux (INESSS)
Dec 19, 2019
MilliporeSigma Licenses Foundational CRISPR Integration Technology to Promega
Dec 09, 2019
IDnow Integrates eID Service from AUTHADA Into its Platform
Dec 04, 2019
Ping An Good Doctor and Merck KGaA, Darmstadt, Germany Form Strategic Collaboration to Advance Intelligent Healthcare in China
Nov 26, 2019
Japan and Singapore Grant CRISPR Patents to MilliporeSigma
Nov 20, 2019
Merck KGaA, Darmstadt, Germany, Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations
Nov 08, 2019
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial
Oct 28, 2019
European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
Oct 22, 2019
Exploratory Analysis Reports Efficacy and Safety of BAVENCIO® (avelumab) Over Three Years in Previously Treated Metastatic Merkel Cell Carcinoma
Oct 08, 2019
Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
Oct 08, 2019
EMD Serono Announces JAMA Publication of Phase II Results of Sprifermin for Osteoarthritis Structure Modification